BiotechTube

Exacyl®

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Blood Loss After a Total Hip Replacement

Conditions

Blood Loss After a Total Hip Replacement

Trial Timeline

Oct 20, 2015 → Aug 29, 2017

NCT ID
NCT02403596

About Exacyl®

Exacyl® is a phase 3 stage product being developed by Bayer for Blood Loss After a Total Hip Replacement. The current trial status is completed. This product is registered under clinical trial identifier NCT02403596. Target conditions include Blood Loss After a Total Hip Replacement.

What happened to similar drugs?

7 of 16 similar drugs in Blood Loss After a Total Hip Replacement were approved

Approved (7) Terminated (6) Active (6)
✅micafungin + voriconazoleAstellas PharmaApproved
✅Bunazosin + Doxazosin + ValsartinEisaiApproved
✅AliskirenNovartisApproved
✅Aliskiren and HCTZNovartisApproved
✅Aspirin 100 mg + PlaceboBayerApproved
✅Hemostatic MatrixBaxterApproved
✅losartan potassium + Comparator: PlaceboOrganonApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02403596Phase 3Completed

Competing Products

20 competing products in Blood Loss After a Total Hip Replacement

See all competitors
ProductCompanyStageHype Score
micafungin + voriconazoleAstellas PharmaApproved
35
CefiderocolShionogiPhase 2
35
Bunazosin + Doxazosin + ValsartinEisaiApproved
43
PegfilgrastimKyowa KirinPhase 2
35
epoetin alfaJohnson & JohnsonPhase 2/3
38
epoetin alfaJohnson & JohnsonPhase 2/3
38
epoetin alfaJohnson & JohnsonPhase 2
35
Metoprolol Succinate + HydrochlorothiazideAstraZenecaPhase 3
40
AZD6140 + PlaceboAstraZenecaPhase 1
29
NKTR-118 + moxifloxacin + PlaceboAstraZenecaPhase 1
29
MEDI-551AstraZenecaPhase 1
29
Ecallantide + Cyklokapron(R)MerckPhase 2
35
DaptomycinMerckPhase 2
35
ecallantide + placeboMerckPhase 2
35
MK0859MerckPhase 1
29
Ecallantide + PlaceboMerckPhase 2
27
HSC835NovartisPhase 2
35
AliskirenNovartisApproved
35
Aliskiren and HCTZNovartisApproved
43
Aliskiren + Amlodipine + Placebo Aliskiren + Placebo AmlodipineNovartisPhase 2
35